Compare Abeona Therapeutics Inc (ABEO) vs Oklo Inc (OKLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Oklo Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Oklo Inc trades at $47.23 (market cap $8.33B). The key difference: Oklo Inc is far larger — about 22.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | OKLO | |
|---|---|---|
Market Cap | $373.32M | $8.33B |
Sector | Health | Technology |
52-Week High | $7.23 | $174.14 |
52-Week Low | $4.17 | $45.58 |
Enterprise Value | $228.22M | $6.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
OKLO trades at $51.84, down 0.99% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $105.66 million for 2025 and negative cash flow from operations. Recent positive developments include DOE safety approval for its Groves Isotope Test Reactor and strategic acquisitions to accelerate reactor development.
Analyst consensus remains strongly bullish with a $96 price target, but execution risks and sustained losses pose challenges. The stock's outlook hinges on successful reactor deployment and achieving profitability amid high cash burn. Investors should weigh the high growth potential against substantial operational and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
